SciClone Pharmaceuticals is a specialty pharmaceutical company with a substantial commercial business in China, as well as a product portfolio of therapies for oncology, infectious diseases, and cardiovascular, urological, respiratory and central nervous system disorders. The company’s ZADAXIN (thymalfasin) has been approved in more than 30 countries. SciClone additionally markets around 15 mostly partnered products in China and is pursuing the registration of several other therapeutic products in that country. For more information, visit the company’s Web site at www.sciclone.com.

Rodman & Renshaw is a full-service investment bank dedicated to providing corporate finance, strategic advisory, and related services to public and private companies across multiple sectors and regions. Rodman also provides research, sales, and trading services. According to Sagient Research Systems, Rodman has been ranked the #1 Placement Agent in terms of the aggregate number of PIPE and RD financing transactions completed every year since 2005. For more information on Rodman & Renshaw, visit www.rodmanandrenshaw.com.

Let us hear your thoughts below: